Related Experiment Videos
Different angiogenic pathways characterize superficial and invasive bladder cancer
T O'Brien1, D Cranston, S Fuggle
1Imperial Cancer Research Fund, University of Oxford, England.
Cancer Research
|February 1, 1995
Summary
Vascular endothelial growth factor (VEGF) and platelet-derived endothelial cell growth factor are key in bladder cancer progression. Elevated VEGF predicts early recurrence in specific superficial bladder tumors.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Research
Background:
- Angiogenesis, the formation of new blood vessels, is crucial for tumor growth and metastasis.
- Two key angiogenic factors, VEGF and platelet-derived endothelial cell growth factor, are implicated in various cancers.
- Understanding their differential roles in bladder cancer stages is vital for targeted therapies.
Purpose of the Study:
- To investigate the expression patterns of VEGF and platelet-derived endothelial cell growth factor in primary bladder tumors and normal bladders.
- To determine the correlation between the expression of these angiogenic factors and bladder cancer stage and differentiation.
- To assess the predictive value of VEGF expression for early recurrence in specific superficial bladder tumors.
Main Methods:
- RNase protection analysis was employed to quantify the expression levels of VEGF and platelet-derived endothelial cell growth factor.
- The study included 45 primary bladder tumors and 8 normal bladder tissues.
- Expression levels were compared across different tumor stages (superficial vs. invasive) and differentiation grades.
Main Results:
- Overall, tumors showed significantly higher expression of both VEGF (3-fold) and platelet-derived endothelial cell growth factor (40-fold) compared to normal bladders.
- VEGF expression was higher in superficial tumors (4-fold vs. invasive), while platelet-derived endothelial cell growth factor was significantly elevated in invasive tumors (33-fold vs. superficial).
- In pT1G1/2 tumors, higher VEGF expression predicted recurrence within 3 months (4-fold increase).
Conclusions:
- Distinct angiogenic pathways involving VEGF and platelet-derived endothelial cell growth factor are active at different stages of bladder cancer.
- These findings support the existence of dual genetic pathways in bladder cancer development.
- Elevated VEGF expression serves as a significant predictor of early recurrence in pT1G1/2 bladder tumors.